[go: up one dir, main page]

MX2010000938A - Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático. - Google Patents

Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.

Info

Publication number
MX2010000938A
MX2010000938A MX2010000938A MX2010000938A MX2010000938A MX 2010000938 A MX2010000938 A MX 2010000938A MX 2010000938 A MX2010000938 A MX 2010000938A MX 2010000938 A MX2010000938 A MX 2010000938A MX 2010000938 A MX2010000938 A MX 2010000938A
Authority
MX
Mexico
Prior art keywords
benzothiazol
morpholin
piperidine
methoxy
amide
Prior art date
Application number
MX2010000938A
Other languages
English (en)
Inventor
Tom Woiwode
Mark Moran
Original Assignee
Synosia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synosia Therapeutics Inc filed Critical Synosia Therapeutics Inc
Publication of MX2010000938A publication Critical patent/MX2010000938A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Métodos para tratar el trastorno por stress postraumático en un paciente con ácido 4-hydroxi-4-metíl-piperidin-1-carboxilico (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida. También se proveen métodos para mejorar la capacidad de recuperación del paciente con ácido 4-hidroxi-4-metil-piperidin-1-carboxilico (4-metoxi-7-morfolin-4-il-beazotiazol-2-il)-amida. También se proveen métodos para diagnosticar el trastorno postraumático en un paciente.
MX2010000938A 2007-07-23 2008-07-23 Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático. MX2010000938A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93503507P 2007-07-23 2007-07-23
PCT/US2008/070934 WO2009015236A1 (en) 2007-07-23 2008-07-23 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder

Publications (1)

Publication Number Publication Date
MX2010000938A true MX2010000938A (es) 2010-07-01

Family

ID=40281808

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010000938A MX2010000938A (es) 2007-07-23 2008-07-23 Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.

Country Status (12)

Country Link
US (1) US20090082341A1 (es)
EP (1) EP2182803A4 (es)
JP (1) JP2010534674A (es)
CN (1) CN101873799A (es)
AU (1) AU2008279169A1 (es)
BR (1) BRPI0814672A2 (es)
CA (1) CA2708323C (es)
CO (1) CO6260011A2 (es)
MX (1) MX2010000938A (es)
NZ (1) NZ583191A (es)
RU (1) RU2500401C2 (es)
WO (1) WO2009015236A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX357542B (es) * 2007-08-06 2018-07-13 Biotie Therapies Inc Nepicastat para usarse en el tratamiento de dependencia.
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2018059531A1 (zh) * 2016-09-30 2018-04-05 苏州晶云药物科技有限公司 一种腺苷a2a受体拮抗剂药物的晶型及其制备方法和用途
MX2022009050A (es) 2020-01-22 2022-10-27 Seelos Therapeutics Inc Reduccion de los efectos secundarios de los antagonistas de nmda.
WO2022167778A1 (en) 2021-02-02 2022-08-11 Haiku Therapeutics Ltd Ebselen as adenosine receptor modulator

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100526487B1 (ko) * 2000-06-21 2005-11-08 에프. 호프만-라 로슈 아게 벤조티아졸 유도체
JP2005516891A (ja) * 2001-09-13 2005-06-09 シェーリング　コーポレイション アデノシンＡ２ａレセプタアンタゴニストと抗鬱薬または抗不安薬との組合せ
KR20060037252A (ko) * 2003-06-10 2006-05-03 교와 핫꼬 고교 가부시끼가이샤 불안 장애의 치료 방법
CN1902196B (zh) * 2003-12-26 2010-12-29 协和发酵麒麟株式会社 噻唑衍生物
GB0403155D0 (en) * 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
DK1753760T3 (da) * 2004-05-24 2008-04-14 Hoffmann La Roche 4-hydroxy-4-methyl-piperidin-1-carboxylsyre-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amid
RU2328977C2 (ru) * 2007-01-15 2008-07-20 Наталья Леонидовна Бундало Способ диагностики посттравматического стрессового расстройства (птср)
JP2010534676A (ja) * 2007-07-23 2010-11-11 シノシア・セラピューティクス 心的外傷後ストレス障害の治療

Also Published As

Publication number Publication date
NZ583191A (en) 2012-06-29
RU2500401C2 (ru) 2013-12-10
CO6260011A2 (es) 2011-03-22
CA2708323C (en) 2013-09-24
JP2010534674A (ja) 2010-11-11
BRPI0814672A2 (pt) 2014-09-30
EP2182803A1 (en) 2010-05-12
US20090082341A1 (en) 2009-03-26
EP2182803A4 (en) 2010-09-01
AU2008279169A1 (en) 2009-01-29
RU2010106023A (ru) 2011-08-27
WO2009015236A1 (en) 2009-01-29
CN101873799A (zh) 2010-10-27
CA2708323A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
HUS2200050I1 (hu) Dóziseszkalációs enzim helyettesítõ terápia savas szfingomielináz elégtelenség kezelésére
EA201170465A1 (ru) Способы лечения прогрессирующего множественного склероза
MX2008013304A (es) Compuestos de peptido 1 tipo glucagon.
MX2010000937A (es) Tratamiento del trastorno por estrés postraumático.
MY172372A (en) Compositions and methods for lowering triglycerides
CO6660423A2 (es) Composiciones y métodos para tratar la enfermedad de gaucher
IL210856A0 (en) Combination therapy for the treatment of diabetes and related conditions
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
GB201016812D0 (en) Method and apparatus for treating respiratory diesease
MX2010000938A (es) Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.
ZA201201222B (en) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-derivatives,methods for the production thereof and use thereof for treating diseases
MX2011008994A (es) Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2.
NZ597115A (en) Method of treating age related disorders with fujimycin
WO2011067711A3 (en) Novel heparanase splice variant
WO2009105507A3 (en) Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
EP2533796A4 (en) METHOD FOR THE TREATMENT OF GLUCOSE TISSUE CHANGES
GEP20156373B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
MY179784A (en) Use of cathepsin h
UA36750U (ru) Способ лечения лейкоплакии слизистой оболочки полости рта
UA56675U (ru) Способ местного лечения генерализованного пародонтита c использованием синглетно-кислородной терапии
UA45538U (ru) Способ лечения астенического синдрома у пациентов урологического профиля
UA37170U (ru) Способ профилактики и лечения тканевой гипоксии при резервировании аутокрови
UA41676U (ru) Способ лечения полипов желудка
UA58941U (ru) Способ оптимизации тактики восстановительного лечения больных глиальными опухолями головного мозга

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BIOTIE THERAPIES, INC.*

FA Abandonment or withdrawal